Modulation of cardiomyocyte contractility and action potentials with chemogenetic chloride currents

  • Sönmez, Muhammed
  • Stüdemann, Tim
  • Manthey, Christoph
  • Covic, Anita
  • Shehata, Nancy
  • Im, Junsoo
  • Schwarzova, Barbora
  • Rössinger, Judith
  • Srikantharajah, Rajiven
  • Shibamiya, Aya
  • Schwedhelm, Edzard
  • Eschenhagen, Thomas
  • Christ, Torsten
  • Weinberger, Florian
The Journal of Physiology Publish Ahead of Print, February 26, 2025. | DOI: 10.1113/JP286428

Transient perturbation of electrical activity is used in neuroscience to study the impact of specific neuronal cell populations on brain function. Similarly, cardiomyocyte (CM) physiology can be controlled by the activation of artificially expressed ion channels. Pharmacologically selective actuator modules (PSAMs) are engineered ligand-gated ion channels that can be activated with small molecules. We aimed to use the ‘inhibitory’ PSAMs, (i) PSAML141F,Y115F-GlyR (PSAM-GlyR) and (ii) PSAML131G,Q139L,Y217F (ultrapotent PSAM4-GlyR), which consist of modified α7-nicotinergic acetylcholine receptor ligand binding domains and the ion pore domain of the glycine receptor, to modulate CM physiology with chloride currents. We employed CRISPR/Cas9 to integrate PSAM-GlyR and PSAM4-GlyR in induced pluripotent stem cells, differentiated CMs and generated engineered heart tissue (EHT). Video optical force recordings, sharp microelectrode action potential measurements and patch-clamp technique were used to characterize PSAM-GlyR and PSAM4-GlyR CMs. PSAM-GlyR and PSAM4-GlyR activation allowed titration of chloride currents in a reversible manner. We found that chloride currents modulated action potential characteristics. Patch clamp recordings showed that channel activation resulted in chloride-driven currents that depolarized the cell. In EHT, this resulted in a stop of contractility that was fully reversible after wash-out. We provide a comprehensive characterization of the chemogenetic tools PSAM-GlyR and PSAM4-GlyR in CMs, demonstrating their utility to modulate CM activity in vitro (PSAM-GlyR and PSAM4-GlyR) but also potential for in vivo applications (PSAM4-GlyR).

Copyright © 2025 John Wiley & Sons, Ltd
View full text|Download PDF